Cap4HR’s Post

🌟 Exciting Milestones for Lys Medical! 🌟 I’m thrilled to share that Lys Medical is achieving major progress and proving its market traction! This confirms our ability to save several weeks in the patient pathway in lung cancer diagnosis (currently 5-6 months on average according to Gidlea et al.) In one year: - The survival rate at 5 years decreases by a factor of 3; - The cost climbs from 7k$ to 17k$/patient /month. We’re seeing incredible momentum thanks to: ✅ Relevant clinical results that validate our innovative solutions and highlight the impact we can have in the medical field, 93% of positive predictive value to help in the visual diagnosis to take the patient in charge even if the biopsy is not conclusive. ✅ First sales that mark a significant turning point in our journey, helping us reach healthcare providers and patients with our technology. We are thrilled that our customer list is increasing, in France, Spain, Belgium and more coming. ✅ Growing interest from partners eager to collaborate as we scale and move toward our next steps. This achievement is a testament to the dedication of our talented team, the trust of our early adopters, and the support of our partners, notably the team of pulmonology in #HUB led by @Dimitri Leduc and our users. Together, we’re transforming healthcare solutions, and this is only the beginning! 🚀 More exciting features are coming. Stay tuned as we continue to push boundaries and make healthcare innovations accessible for more people. Thank you to everyone who has been part of this journey so far! #Innovation #Healthcare #MedicalDevices #LysMedical #Growth Gildea, T. R., DaCosta Byfield, S., Hogarth, D. K., Wilson, D. S., & Quinn, C. C. (2017). A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. ClinicoEconomics and Outcomes Research, 261-269.